1.42
+0(+0.00%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.19 |
| Day High | 1.42 |
| Day Low | 1.19 |
| 52-Week High | 21 |
| 52-Week Low | 1.12 |
| Volume | 808,780 |
| Average Volume | 218,513 |
| Market Cap | 32.92M |
| PE | -0.13 |
| EPS | -10.8 |
| Moving Average 50 Days | 1.96 |
| Moving Average 200 Days | 4.41 |
| Change | 0 |
If you invested $1000 in Lunai Bioworks Inc. (RENB) since IPO date, it would be worth $24.07 as of January 09, 2026 at a share price of $1.42. Whereas If you bought $1000 worth of Lunai Bioworks Inc. (RENB) shares 5 years ago, it would be worth $43.83 as of January 09, 2026 at a share price of $1.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
GlobeNewswire Inc.
Jun 03, 2025 1:15 PM GMT
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, tod
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire Inc.
May 22, 2025 7:12 PM GMT
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedit
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire Inc.
May 22, 2025 3:05 PM GMT
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedit